The largest database of trusted experimental protocols
Sourced in United States

The CRL-1772 is a laboratory equipment product from American Type Culture Collection. It is designed for cell culture applications. The core function of this product is to provide a controlled environment for the growth and maintenance of cells in vitro.

Automatically generated - may contain errors

93 protocols using crl 1772

1

Cell Culture and Differentiation of C2C12 and PC12 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cell culture of C2C12 mouse myoblasts (American Type Culture Collection (ATCC), CRL-1772) and PC12 rat adrenal gland pheochromocytoma cells (ATCC, CRL-1772) was performed as previously reported9 (link)–13 (link),15 (link). In brief, C2C12 cells were cultured in DMEM with 10% FBS and 1% penicillin–streptomycin (Invitrogen). Cells were seeded onto a 24-well plate at 50,000 cells per ml and incubated for 10–14 days in DMEM with 1% FBS and 1% penicillin–streptomycin to differentiate into myotubules. PC12 cells were grown in DMEM with 12.5% horse serum, 2.5% FBS and 1% penicillin–streptomycin. Cells were seeded onto a 24 well-plate, and 50 ng ml−1 nerve growth factor (Invitrogen) was added 24 h after seeding.
+ Open protocol
+ Expand
2

C2C12 Myoblast Encapsulation for Bioprinting

Check if the same lab product or an alternative is used in the 5 most similar protocols
C2C12 immortalized mouse myoblasts (CRL-1772TM, ATCC) were cultured in T75 and T175 flasks with proliferation medium: Dulbecco’s Modified Eagle Medium, high glucose, pyruvate (Gibco, 11995-081); qualified, heat-inactivated fetal bovine serum (Gibco, 16140-071) at 10% (v/v); and penicillin-streptomycin (Gibco, 15070-063) at 1% (v/v). When the cells reached above 80% confluency, they were suspended using a 0.05% of Trypsin-EDTA solution (Gibco, 15400054), diluted in DPBS, and reseeded into a new flask at an appropriate seeding density to enable cell expansion. Once an adequate number of cells were generated, the cells were again suspended, counted, and encapsulated in the gelatin bioink warmed to 37 °C at concentrations of 1, 10, and 30×106 cells/mL for rheological and cell printing tests.
+ Open protocol
+ Expand
3

C2C12 Myoblast Differentiation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
C2C12 myoblast cells (ATCC® CRL-1772 TM) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% Fetal Bovine Serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA), 1% penicillin–streptomycin (Thermo Fisher Scientific, USA) in a humidified incubator at 37 °C and 5% CO2. Subsequently, the cells were transferred to and cultured in 6-well plates (1 × 105 cells/well). C2C12 myoblasts were collected or induced to undergo myogenic differentiation after transfections with mimic-miR-155-5p. For differentiation, once the myoblasts reached 80–90% confluence, the growth medium was replaced with FBS-free, DMEM-containing Horse Serum (2%), L-glutamine, and penicillin/streptomycin (1%) for 120 h. All experiments were performed in triplicate for each group.
+ Open protocol
+ Expand
4

Culturing BJ and C2C12 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human BJ fibroblasts (CRL-2522) and C2C12 mouse myoblasts (CRL-1772TM) were obtained from ATCC. Culture media and reagents were purchased from (Invitrogen™, United States), unless indicated otherwise. BJ cells were cultured in Eagle’s minimum essential medium (EMEM). C2C12 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM). The culture media for both cell lines were supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin. Cells were grown at 37°C in a 5% CO2 atmosphere.
+ Open protocol
+ Expand
5

C2C12 Myotube Differentiation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse C2C12 myoblasts (CRL-1772TM, ATCC, Manassas, VA, USA) were maintained in DMEM supplemented with 10% FBS and 1% PS at 37 °C in a 5% CO2 humidified incubator. When the confluence of the cells reached 80%, the culture medium was replaced with 2% horse serum (HS) containing DMEM to induce myotube differentiation, and the cells were incubated for 7 days with medium replacement every 24 h. The cells were then serum-starved overnight before PEG-BHD1028 or human gAcrp30 (gAD) treatment.
+ Open protocol
+ Expand
6

Culturing and Differentiating Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
MDA-MB-231 breast cancer cells38 (link) (HTB-26, ATCC, Manassas, VA), MCF-7 breast cancer cells39 (link) (HTB-22, ATCC), ZR75-1 breast cancer cells40 (link) (CRL-1500, ATCC), PC-3 prostate cancer cells41 (link) (CRL-1435, ATCC), and RWGT2 lung cancer cells15 (link),42 (link) (isolated from bone metastases by Dr. Guise as reported15 (link)) were cultured in Dulbecco's modified Eagle's media (DMEM) (Hyclone, Logan, UT) containing 10% heat-inactivated fetal bovine serum (FBS) (Hyclone). JJN-3 multiple myeloma cells43 (link) (ACC 541, DSMZ) were cultured in RPMI 1640 (Invitrogen, Grand Island, NY) containing 10% heat-inactivated FBS. A549 cancer cells (CCL-185, ATCC) were cultured in 1640 RPMI (Hyclone) containing 10% heat-inactivated FBS. C2C12 myoblast cells (CRL-1772, ATCC) were cultured subconfluently in DMEM containing 10% heat-inactivated FBS. C2C12 myoblasts were differentiated into myotubes by culture in DMEM containing 2% heat-inactivated horse serum (HS) (Hyclone). All cells were maintained at 37° C with 5% CO2 in a humidified chamber. All cells were verified to be free of mycoplasma contamination via routine PCR testing. No independent verification was completed. Cells treated with recombinant human TGF-β1 (R&D Systems, Minneapolis, MN) were starved in DMEM (no serum) for 16-20 hrs and 5 ng/ml TGF-β1 was added to cells in DMEM.
+ Open protocol
+ Expand
7

Stem/progenitor cell culture protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two different types of cells were used to model stem/progenitor cells for in vitro studies. Multipotent mouse C2C12 myoblasts (ATCC® CRL-1772™, Manassas, VA, US) were cultured in Dulbecco's modified Eagle's media (DMEM, Thermo Fisher Scientific Inc.) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific Inc.) and 1% penicillin-streptomycin (PS, 10,000 U/mL, Fisher Scientific). Poietics™ human mesenchymal stem cells (hMSCs) (PT-2501, Lonza Walkersville Inc. MD) were cultured with mesenchymal stem cell growth medium (MSCGM™ BulletKit™, PT-3001, Lonza Walkersville Inc. MD). All the cells were kept at 37 °C, 5% CO2 in a humidified incubator. No mycoplasma contamination was found in cell cultures, which was monitored using a mycoplasma detection kit (Nanjing Vazyme Biotech Co., Ltd. China, MycoBlue, #D101-02) and Hoechst 33342 (Anaspec, USA) staining.
+ Open protocol
+ Expand
8

C2C12 Mouse Myoblast Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
C2C12 mouse myoblast cells were obtained from a commercial vendor (ATCC Cat# CRL-1772, RRID: CVCL_0188). Cells were cultured at 37°C with 5% CO2 in a humidified incubator in media consisting of Dulbecco’s modified Eagle medium (DMEM; Gibco #11995-065) supplemented with 1% v/v penicillin-streptomycin (Gibco #15140-122) and either 10% v/v FBS (Gibco #A3161001) for proliferation media or 2% v/v horse serum (Gibco #16050-130) for differentiation media. Cells were grown in T75 flasks to ~80% confluence then washed with sterile PBS wash and detached (Gibco TrypLE Express #LTS12604021) for passaging. Cells used for all experiments were ≤9 passages from stock and were seeded into 6-well plates for experiments unless otherwise stated.
+ Open protocol
+ Expand
9

C2C12 Cell Differentiation and Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
C2C12 cells (passages 4–17, CRL-1772; ATCC, Manassas, VA, USA) were incubated at 37 °C in a 5% CO2 atmosphere. The C2C12 cells were cultured in DMEM with 4500 mg/L D-glucose, 584 mg/L L-glutamine, 110 mg/L sodium pyruvate, 1200 mg/mL sodium bicarbonate, 100 Units/mL penicillin, 100 µg/mL streptomycin, and 10% FBS. For C2C12 differentiation, 9 × 104 cells were seeded and then, cells at 70–80% confluence were replaced with the differentiation medium containing DMEM supplemented with 2% horse serum for 6 days. The C2C12 cells were treated with ECR (50 and 100 µg/mL) and DEX (39.2 µg/mL) for 24 h. The assessments of ECR on cell viability were performed using 3-(4,5-dimethylthiazol-2-yl) (MTT; Duchefa Biochemie, Haarlem, The Netherlands) as previously described [53 (link)].
+ Open protocol
+ Expand
10

Culturing Primary Cells and Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary normal human dermal fibroblasts (HDMFs; ATCC® PCS-201-010™) were maintained in DMEM medium (GIBCO) containing 20% FBS (Seradigm), 0.2 mM L-Glutamine (Gibco), and 100 U/ml penicillin/streptomycin (Gibco). Murine myoblasts (C2C12; ATCC® CRL-1772) were cultured in DMEM medium + GlutaMAX™ (Gibco) containing 10% FBS (Seradigm) and 100 U/ml penicillin/streptomycin (Gibco). Primary patient-derived CMCs were propagated in Ham’s F12 medium (Gibco) supplemented with 10% FBS (Seradigm), 20 ng/ml Recombinant Human bFGF (PeproTech), 0.2 mM L-Glutamine (Gibco), 0.005 U/ml human Erythropoietin (Sigma), and 100 U/ml penicillin/streptomycin (Gibco). Human HEK293FT cells (Life Technologies) used in lentiviral production were grown in DMEM medium (Gibco) containing 10% FBS (Seradigm) and 0.2 mM L-Glutamine (Gibco). All cell lines were propagated under standard incubation conditions at 37°C with 5% atmospheric CO2 and, further, were enzymatically passaged using TrypLE™ (Life Technologies) when approaching ≈70% confluence.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!